Global MEK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights.
Global MEK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global MEK Inhibitors Market Opportunity Assessment: > USD 3 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 4 Drugs ( Trametinib, Binimetinib, Selumetinib, Cobimetinib)
- Approved MEK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report: https://www.kuickresearch.com/report-mek-map-kinase-inhibitor-market-size-clinical-trials-report
Mitogen activated protein kinase (MAPK) pathway or RAS-RAF-MEK-ERK pathway, involves the regulation of cell proliferation and survival. It is constitutionally overactive in 30% of cancers. Two enzymes in this pathway, namely, BRAF and MEK, are target kinases which play crucial roles in the cell cycle. Researchers first developed target therapies to target BRAF pathway, however intrinsic and acquired tumor resistance quickly led to treatment failure by reactivation of the MAPK pathway. MEK inhibitors have emerged to partially overcome these resistance mechanisms and are now used in combination with BRAF inhibitors to extend the time to resistance.
The novel MEK inhibitors bind to and inhibit MEK, inhibiting MEK-dependent cell signaling. This inhibition leads to cell death and the inhibition of tumor growth. These are allosteric binding inhibitors of MEK which inhibit either MEK1 alone, or both MEK1 and MEK2. Mekinist (Trametinib) developed by GlaxoSmithKline was the first MEK inhibitor approved by regulatory bodies in 2014. The drug in combination with Tafinlar (dabrafenib) is indicated for the treatment of patients with unresectable/metastatic melanoma with BRAF V600E or V600K mutations. Later, three other MEK inhibitors including Cotellic, Mektovi and Koselugo also entered the market for the management of wide range of cancers.
Apart from approved therapeutic indications, several ongoing clinical trials are also evaluating the role of approved drugs in other cancers which will also drive the growth of market in the forthcoming years. For instance, recent clinical trial demonstrated that MEK inhibitor trametinib (Mekinist) reduced the risk of disease progression or death by 52% compared with current standard-of-care (SOC) therapies in patients with relapsed or persistent low-grade serous ovarian carcinoma, making it the potential new SOC for this patient population. This trial suggested that rametinib would be the most favorable option at first relapse for in patients administered chemotherapy followed by aromatase inhibitor in the frontline setting.
The pharmaceutical industry is historically notorious for its confidentiality, but collaborations between big pharmaceutical companies and biotechs are becoming a more common way to share the high risk of bringing new therapeutics to the market. For instance, Array Biopharma and Bristol Myers Squibb have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array’s investigational MEK inhibitor, binimetinib in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors. In addition to this, BeiGene also expanded collaboration with Novartis for the commercialization of Mekinist in China.
As per our report findings, global MEK inhibitor market is expected to grow at a formidable rate and the market is expected to surpass US$ 3 Billion by 2026. Some of the key factors propelling market growth include rise in awareness about MEK inhibitors, surge in product approvals, increase in incident of cancer diseases, and increase in investment from pharmaceutical companies. However, cost of treatment and lack of funds in conducting research are likely to restraint the market. In addition, increase in adoption of MEK inhibitors for newer applications, and emerging economies such as China, India and others, will create new opportunities for global kinase inhibitors market.
The report offers comprehensive insights of the pipeline therapeutics scenario and growth prospects across Mitogen Activated Protein Kinase (MEK or MAP2K) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, commercial information of already available MEK inhibitor, and sales forecast till 2026. On the basis of indication, the market has been segmented into melanoma, lung cancer, colorectal cancer, breast cancer, and thyroid cancer. The report also provides regional analysis of the MEK inhibitor market in US, Europe, China, and Japan.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366